• For Individuals
  • For Institutions
  • Download
  • Help
  • About

longbridgelongbridge
longbridgelongbridge
Why Longbridge?
Investment Products
Trading Tools
Trading Platform
Developers
Market Data Services
Analysis Tools
News Services
Dolphin Research
Pricing
Markets
Global Markets
Stock Screener
Information
Research
News
Live
Community
Academy
Promotions
PortAI
LB Café
EN
English
简体中文
繁體中文
繁體中文(廣東話)Posts & comments will be shown in Cantonese
Search...
Quote ListQuote List
Overview
Posts
News
Financials
© 2025 Longbridge|Disclaimer

Event Tracking

Nov27
Protagonist Therapeutics Sees Significant Revenue Growth with Janssen Collaboration
22:45
Nov14
H.C. Wainwright Analyst Reiterates Buy Rating on Protagonist Therapeutics
23:42
Nov9
Protagonist Therapeutics Reports Lower-than-Expected Quarterly Earnings, Stock Price Drops
03:53
Nov7
H.C. Wainwright Maintains Buy Rating on Protagonist Therapeutics
12:02
Protagonist Therap released FY2025 9 Months Earnings on November 6, 2025 (EST), with actual revenue of USD 38.58 M and EPS of USD -1.3599
04:00
Protagonist Therap released FY2025 Q3 earnings on November 6 (EST), actual revenue USD 4.712 M (forecast USD 4.136 M), actual EPS USD -0.62 (forecast USD -0.6375)
04:00

Schedules & Filings

Schedules
Filings
Nov6
Earning Release(EST)

FY2025 Q3 Earning Release (USD) Revenue 4.712 M, Net Income -39.34 M, EPS -0.62

Aug6
Earning Release(EST)

FY2025 Q2 Earning Release (USD) Revenue 5.546 M, Net Income -34.77 M, EPS -0.5499

May6
Earning Release(EST)

FY2025 Q1 Earning Release (USD) Revenue 28.32 M, Net Income -11.66 M, EPS -0.1899

View More

Stock List

Top Gainers
Top Decliners
China Concepts
Symbol
Price
%Chg
Change
SEVNR
0.0280
+218.18%
+0.019
SMX
141.000
+141.07%
+82.510
PLRZ
14.500
+104.51%
+7.410
PMI
3.690
+82.67%
+1.670
SNCR
8.710
+64.34%
+3.410
PMCB
1.210
+54.22%
+0.425
QCLS
6.920
+48.18%
+2.250
ANPA
21.860
+40.67%
+6.320
HYNE
14.000
+40.00%
+4.000
ASTX
46.070
+36.50%
+12.320
View More